Potential Risks Associated with Onivyde for Metastatic Pancreatic Ductal Adenocarcinoma
Onivyde (nal-IRI) is a liposomal encapsulation of irinotecan, used in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based therapy [1]. As with any medication, Onivyde carries potential risks.
What are the most serious side effects of Onivyde?
The most serious risks associated with Onivyde include severe diarrhea and severe myelosuppression (low blood cell counts) [1]. Diarrhea can be life-threatening, leading to dehydration, electrolyte imbalance, and kidney failure. Myelosuppression can result in increased susceptibility to infections, bleeding, and anemia [1].
What common side effects can patients expect with Onivyde?
Common side effects reported in clinical trials for Onivyde, when used in combination, include fatigue, diarrhea, nausea, vomiting, decreased appetite, stomatitis (inflammation of the mouth), and fever [1].
How is Onivyde managed for patients experiencing side effects?
Management of Onivyde side effects typically involves dose modification or interruption, and supportive care. For diarrhea, anti-diarrheal medications are prescribed. For myelosuppression, blood transfusions and growth factors may be administered to help restore blood cell counts [1].
What is the FDA's Black Box Warning for Onivyde?
Onivyde carries a Boxed Warning regarding the risks of diarrhea and myelosuppression. Patients must be monitored closely for these adverse events [1].
Can Onivyde cause liver problems?
While not as common as diarrhea or myelosuppression, Onivyde can cause liver enzyme elevations. Patients receiving Onivyde should have their liver function monitored [1].
Are there any specific monitoring requirements for Onivyde treatment?
Regular monitoring of blood cell counts (complete blood count), electrolyte levels, and kidney function is essential during Onivyde treatment [1].
What patient populations are at higher risk for Onivyde side effects?
Patients with pre-existing liver impairment or those who are elderly may be at increased risk for certain side effects, and may require closer monitoring or dose adjustments [1].
How does Onivyde differ from other pancreatic cancer treatments?
Onivyde is a liposomal formulation of irinotecan, which may alter its pharmacokinetic profile compared to non-liposomal irinotecan. It is indicated for patients whose disease has progressed after initial gemcitabine-based chemotherapy, positioning it as a second-line or later treatment option [1].
What is the prognosis for patients treated with Onivyde?
Clinical trials have shown that Onivyde, in combination therapy, can improve overall survival and progression-free survival compared to other treatment regimens in patients with metastatic pancreatic adenocarcinoma who have progressed on gemcitabine-based therapy [1].
When does the patent for Onivyde expire?
Information on specific patent expiry dates for Onivyde is available through resources like DrugPatentWatch.com [2].
What are the risks of overdose with Onivyde?
There is no specific information provided regarding overdose symptoms with Onivyde in the provided material. However, overdose of irinotecan, the active component, can exacerbate known toxicities such as severe diarrhea and myelosuppression [1].
What alternative treatments are available for metastatic pancreatic cancer after gemcitabine failure?
Beyond Onivyde, other treatment options for metastatic pancreatic cancer after gemcitabine failure may include other chemotherapy regimens, targeted therapies, or participation in clinical trials. These options are determined on a case-by-case basis by an oncologist [1].
*
**Sources:
[1] https://www.onivyde.com/
[2] https://drugpatentwatch.com/